Precigen Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Thanks for joining us for another session at the 44th JP Morgan Healthcare Conference. I'm Brian Cheng. I'm the senior biotech analyst at the firm. On stage, we have Precigen Therapeutics. I will now pass the mic to them for a short presentation followed by a live audience Q&A. Helen, the stage is yours.
Thank you very much, Brian, and thank you for the invitation to the JPMorgan meetings. And, I would say good morning or, noon to some of the audience that are on the webcast. Today, what I would like to do is take you through the advancements of our portfolio at PRI.
Obviously, I would be making some forward-looking, statements. Please, read that.
And, first of all, I just want to introduce really, for those of you who might not be familiar with Prestogen and Prestogen story, who we are. We are a biotech company that has focused on a cell and gene therapy
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
